NASDAQ:MDWD - Mediwound Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.72 +0.01 (+0.21 %)
(As of 02/19/2019 04:18 AM ET)
Previous Close$4.71
Today's Range$4.65 - $4.85
52-Week Range$3.76 - $7.35
Volume59,334 shs
Average Volume855,924 shs
Market Capitalization$127.68 million
P/E Ratio-7.61
Dividend YieldN/A
Beta0.69
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.50 million
Book Value$0.36 per share

Profitability

Net Income$-22,140,000.00
Net Margins-477.34%

Miscellaneous

Employees76
Market Cap$127.68 million
OptionableNot Optionable

Mediwound (NASDAQ:MDWD) Frequently Asked Questions

What is Mediwound's stock symbol?

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

How were Mediwound's earnings last quarter?

Mediwound Ltd (NASDAQ:MDWD) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.05. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.96 million. Mediwound had a negative return on equity of 400.37% and a negative net margin of 477.34%. View Mediwound's Earnings History.

When is Mediwound's next earnings date?

Mediwound is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Mediwound.

What price target have analysts set for MDWD?

2 brokerages have issued twelve-month price targets for Mediwound's stock. Their forecasts range from $11.00 to $15.00. On average, they anticipate Mediwound's share price to reach $13.00 in the next year. This suggests a possible upside of 175.4% from the stock's current price. View Analyst Price Targets for Mediwound.

What is the consensus analysts' recommendation for Mediwound?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.

Has Mediwound been receiving favorable news coverage?

Press coverage about MDWD stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mediwound earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days.

Who are some of Mediwound's key competitors?

Who are Mediwound's key executives?

Mediwound's management team includes the folowing people:
  • Mr. Gal Cohen, Pres & CEO (Age 46)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
  • Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
  • Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
  • Dr. Ety Klinger, Chief R&D Officer (Age 57)

Who are Mediwound's major shareholders?

Mediwound's stock is owned by many different of institutional and retail investors. Top institutional shareholders include United Services Automobile Association (0.73%), Millennium Management LLC (0.25%), BOKF NA (0.22%), ETF Managers Group LLC (0.18%) and Sargent Investment Group LLC (0.05%).

Which major investors are selling Mediwound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including BOKF NA and United Services Automobile Association.

Which major investors are buying Mediwound stock?

MDWD stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Millennium Management LLC and Sargent Investment Group LLC.

How do I buy shares of Mediwound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mediwound's stock price today?

One share of MDWD stock can currently be purchased for approximately $4.72.

How big of a company is Mediwound?

Mediwound has a market capitalization of $127.68 million and generates $2.50 million in revenue each year. The biopharmaceutical company earns $-22,140,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Mediwound employs 76 workers across the globe.

What is Mediwound's official website?

The official website for Mediwound is http://www.mediwound.com.

How can I contact Mediwound?

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]


MarketBeat Community Rating for Mediwound (NASDAQ MDWD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel